Share Name Share Symbol Market Type Share ISIN Share Description
Sinclair Pharma LSE:SPH London Ordinary Share GB0033856740 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.40p -1.80% 21.85p 21.70p 22.00p 22.90p 22.90p 22.90p 224,268 16:35:25
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 45.5 -38.2 -5.9 - 110.07

Sinclair Pharma (SPH) Latest News

More Sinclair Pharma News
Sinclair Pharma Takeover Rumours

Sinclair Pharma (SPH) Share Charts

1 Year Sinclair Pharma Chart

1 Year Sinclair Pharma Chart

1 Month Sinclair Pharma Chart

1 Month Sinclair Pharma Chart

Intraday Sinclair Pharma Chart

Intraday Sinclair Pharma Chart

Sinclair Pharma (SPH) Discussions and Chat

Sinclair Pharma Forums and Chat

Date Time Title Posts
11/2/201812:09Sinclair Pharma Thread1,695
15/10/201414:32TipTV: Sinclair Pharmaceuticals to head back towards 30p!-
21/2/200508:49Small cap Sinclair Pharma - Walmart inc.-

Add a New Thread

Sinclair Pharma (SPH) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2018-02-19 15:56:4421.881,800393.86O
2018-02-19 15:56:3021.8831,9046,979.00O
2018-02-19 15:27:5121.88150,00032,812.50O
2018-02-19 12:57:4722.0017,2173,787.74O
2018-02-19 12:26:2022.0017,3003,806.02O
View all Sinclair Pharma trades in real-time

Sinclair Pharma (SPH) Top Chat Posts

Sinclair Pharma Daily Update: Sinclair Pharma is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SPH. The last closing price for Sinclair Pharma was 22.25p.
Sinclair Pharma has a 4 week average price of 20.50p and a 12 week average price of 20.50p.
The 1 year high share price is 36p while the 1 year low share price is currently 20.50p.
There are currently 503,768,952 shares in issue and the average daily traded volume is 62,552 shares. The market capitalisation of Sinclair Pharma is £110,073,516.01.
dealit: 3 positive announcements good to see, lets hope that the share price keeps moving North.
haroldthegreat: Write up in evening standard on Friday on apprentice winner Dr Leah says she is using silhouette in her clinics for non surgical face lifts.that should increase demand by patients for the product in London. She and Lord Sugar would have done very careful research before using the product in their 3 clinics as they are in the public eye and cannot be associated with a product that doesn't live up to expectations. Whereas any other salon or plastic surgeon stating they use the product would have limited effect on sales the apprentice effect should see a significant uplift on future sales. This is the first time I have seen it mentioned in any publication I read. Hopefully it should result in a share price increase next week in anticipation of increased sales .
steeplejack: A long,meandering statement."Local issues"?....what happened,someone go on strike.We can't apply the expression "firing on all cylinders".Both geographically and divisionally,there are weak spots.The share price is likely to hang around current levels given that recent price weakness has probably discounted this rather bland message.
maxwellsdemon: It is ABZA. Top mover today.
digger18: I tend to agree and feel that this is down to the significant changes made with the restructuring and the market wants to see a good set of figures. If this comes to fruition which I believe will be the case, then we should see the share price reflecting performance. It will be interesting to see the cash burn relating to the new marketing strategy.
steeplejack: Since the stock is not overtly expensive,a share price falling towards a three year low is bound to raise concern.No smoke without fire etc.I'm reassured that Tosca are more than capable of addressing any problems,if indeed there are any.
dealit: The only thing that I cannot understand is the share price, the potential growth here is massive, growth usually drives a Companies share price North.
soundbuy: H/T FT AV Jefferies BUY US Silhouette strategy executed: Sinclair has granted Almirall's (ALM SM, Hold, €13.4) Thermi subsidiary the rights to market Silhouette InstaLift in the US. Thermi already markets a portfolio of minimally invasive aesthetics products using temperature controlled radio frequency to treat nerve and soft tissue conditions, such as excessive skin laxity, glabellar frown lines, and cellulite, employing the “Science of Heat”. We see strong synergies between Silhouette and Thermi with the current 55 rep salesforce to be expanded. Thermi has demonstrated commercial acumen, in our view, growing sales since launch in 2013 from c.$11m 2014 to c.$30m 2015 with over 1,000 systems now placed. Hence we believe as a partner Thermi is well-placed to maximise Silhouette's commercial potential for Sinclair, also removing the uncertainty as to the optimal S&M strategy. The distribution deal is initially for four years until mid-2020 with Sinclair having the right to regain the brand. Financial terms of the collaboration are undisclosed but we understand Sinclair is funding Thermi's incremental launch spend. Doug Abel, Sinclair US President, will head the Silhouette marketing committee ensuring the company retains some control of the roll-out. Silhouette has significant potential: FDA approved Silhouette Instalift at end-April 2015 for the minimally invasive repositioning and tightening of facial skin using resorbable sutures and bidirectional cones. We believe a US clinical study is ongoing with the aim of simplifying the FDA approved labelling for the insertion technique, bringing it in-line with other geographies, with results anticipated in 4Q16E. Based on the European roll-out, management believes c.4,000 US physicians could use Silhouette Instalift an average 4x monthly at peak, suggesting peak US sales of at least $200m. At this time we include only a heavily risk-adjusted contribution from the US in our forecasts of sub-£25m revenues. Entering Brazil to broaden footprint: Regaining distribution rights for Silhouette Soft in Brazil enables Sinclair to establish an affiliate in this important aesthetic dermatology market. This transaction is expected to be sales and EPS accretive, also enabling the direct sales of Perfectha, and potentially Ellanse in future once approved. Trading update broadly as expected: Management reports current trading is "strong" with £8.9m sales 1Q16 (+37% in-market) vs. £7.7m for the entirety of 2H15. The c.+40% target for in-market performance of the portfolio is reiterated. Note re-basing inventories will likely curtail reported revenues. Strategic review ended: The prolonged strategic review has finally completed with the Offer Period ended. The Board believes the Thermi collaboration and Brazil deal, together with £45m net cash at end-March 2016, position the company for long-term growth as an independent entity. Attractive growth profile: We see a strong strategic rationale in focusing on a portfolio of dermal fillers, in addition to Silhouette for minimally invasive face-lifts. These brands form a unique aesthetic dermatology franchise, in our view, which with targeted S&M efforts should drive substantial operating leverage with the promise of long product lifecycles. Our 60p/share Price Target suggests an EV around £215m implying 4.2x and 3.4x revenues, or 19x and 13x EBITDA, in FY17E and FY18E, respectively, which we view to be still relatively conservative.
soundbuy: H/T FT AV Stifel BUY Sinclair Pharma has announced it has signed a licensing agreement with Almirall’s aesthetics business Thermigen to launch, distribute and promote Silhouette InstaLift in the US for an initial four-year period. Sinclair has also provided a 3Q FY16 trading update with revenues of £8.9m in the period. The decision to license Silhouette to Almirall marks the end of the company’s strategic review and hence the offer period. The deal also means Sinclair will no longer have to fully fund the product’s US launch. With £45m net cash at 31 March 2016, the business is well funded to profitability. We value Sinclair on a sum-of-the-parts basis at 49p/share, offering significant upside to the current share price. Much of this value rests with Silhouette Instalift in the US. Partnering with an established aesthetics company like Thermigen gives us increased confidence that the products potential can be successfully realised. Buy. Sinclair signs distribution and marketing agreement with Thermigen. As part of the deal, Thermigen will promote Sinclair’s aesthetic product Silhouette InstaLift with its 55 rep sales force with a further 10 reps added to specifically promote Silhouette. The distribution agreement, which is initially for a four-year term, provides for Sinclair to repatriate rights from the end of 2018. Thermigen is a fast growing aesthetics business that was acquired by Almirall in February 2016. It has an installed base of over 1,000 systems in the US that provide a range of thermal aesthetic treatments. Silhouette US launch ongoing. Sinclair initiated US prelaunch activities for Silhouette InstaLift in 4Q15 and has now trained 75 physicians in using the product. Thermigen will formally launch the product later this month. Trading update. Along with this announcement, Sinclair has provided a trading update for 1Q16. Sales in the period were £8.9m, significantly ahead of the £7.7m achieved in 2H15 and given likely seasonal demand for aesthetics in 2Q16, on track for our FY16 forecasts. Sinclair has announced it will change its year-end to 31 December to align the business with industry peers. Brazilian affiliate established for Silhouette Soft effective 1 July 2016. The deal is expected to be immediately accretive. Reiterate Buy. We believe the licensing of distribution and marketing rights to Thermigen not only reduces the investment needed to establish Silhouette InstaLift in the US but also increases the chances of a successful launch given Thermigen’s proven experience. Given Sinclair retains the long-term value in Silhouette InstaLift in the US, we retain our 49p sum-of-the-parts valuation.
gobbie100: Always a danger. If you look at valuation at the moment, a share price of 34p equates to a current value of just £90m for the current business ie 18p a share if you assume that the £80m in cash makes up the other 16p a share. THis would seem a pretty low valuation and thus if no deal can be done could see the company taken private. Shares are pretty tightly held across a small number of institutions. Just depends what they would be willing to accept.
Sinclair Pharma share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V: D:20180220 02:13:01